Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects
- 1 October 2013
- journal article
- research article
- Published by Elsevier BV in Archives of Cardiovascular Diseases
- Vol. 106 (10), 517-527
- https://doi.org/10.1016/j.acvd.2013.06.055
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery diseaseAtherosclerosis, 2013
- Meta-Analysis of Cytochrome P450 2C19 Polymorphism and Risk of Adverse Clinical Outcomes Among Coronary Artery Disease Patients of Different Ethnic Groups Treated With ClopidogrelThe American Journal of Cardiology, 2012
- Effects ofCYP2C19Genotype on Outcomes of Clopidogrel TreatmentNew England Journal of Medicine, 2010
- Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trialThe Lancet, 2010
- Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrelMolecular Biology Reports, 2010
- Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor CoadministrationJournal of the American College of Cardiology, 2010
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel TherapyJAMA, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsNew England Journal of Medicine, 2009
- Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyThe Lancet, 2009